Advertisement
Australia markets closed

  • ALL ORDS

    7,806.00
    -92.90 (-1.18%)
     

  • ASX 200

    7,555.70
    -86.40 (-1.13%)
     

  • AUD/USD

    0.6402
    -0.0024 (-0.37%)
     

  • OIL

    84.41
    +1.68 (+2.03%)
     

  • GOLD

    2,398.20
    +0.20 (+0.01%)
     

  • Bitcoin AUD

    96,681.92
    +1,143.74 (+1.20%)
     

  • CMC Crypto 200

    1,280.70
    -31.93 (-2.43%)
     

  • AUD/EUR

    0.6018
    -0.0013 (-0.22%)
     

  • AUD/NZD

    1.0888
    +0.0013 (+0.12%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,837.40
    +67.38 (+0.38%)
     

  • Hang Seng

    16,140.06
    -245.81 (-1.50%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.65%)
     

Has Amedisys (AMED) Outpaced Other Medical Stocks This Year?

Zacks
In the latest trading session, Lockheed Martin (LMT) closed at $287.71, marking a -1.55% move from the previous day.

Investors focused on the Medical space have likely heard of Amedisys (AMED), but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of AMED and the rest of the Medical group's stocks.

Amedisys is one of 841 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. AMED is currently sporting a Zacks Rank of #1 (Strong Buy).

The Zacks Consensus Estimate for AMED's full-year earnings has moved 5.65% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

ADVERTISEMENT

Our latest available data shows that AMED has returned about 147.20% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 1.12% on average. This shows that Amedisys is outperforming its peers so far this year.

To break things down more, AMED belongs to the Medical - Outpatient and Home Healthcare industry, a group that includes 17 individual companies and currently sits at #152 in the Zacks Industry Rank. Stocks in this group have lost about 3.55% so far this year, so AMED is performing better this group in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track AMED. The stock will be looking to continue its solid performance.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Amedisys, Inc. (AMED) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.